Wang Jiaming, Tian Yu, Shi Xin, Feng Zhaohai, Jiang Lei, Hao Yujun
Department of Neurosurgery, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China.
Department of Neurosurgery, Shenzhen University General Hospital and Shenzhen University Clinical Medical Academy Centre, Shenzhen University, Shenzhen, China.
Front Hum Neurosci. 2022 May 6;16:849069. doi: 10.3389/fnhum.2022.849069. eCollection 2022.
The past four decades have seen the growing use of tissue or cell transplants in Parkinson's disease (PD) treatment. Parkinson's cell therapy is a promising new treatment; however, efficacy of cell transplantation for Parkinson's disease are entirely unclear.
To conduct a meta-analysis and a systematic review of the efficacy of cell therapy in patients with PD.
A systematic literature review and meta-analysis of 10 studies were performed to assess the efficacy of cell therapy in Parkinson's patients. To achieve this, we compared the change in Unified Parkinson's Disease Rating Scale (UPDRS) II and III scale scores to baseline and assessed the incidence of transplant-related adverse events. The MINORS score and the I index were applied to evaluate the quality of studies between-study heterogeneity, respectively.
The literature search yielded 10 articles ( = 120). The improvement in motor function based on the UPDRSIII assessment was -14.044 (95% CI: -20.761, -7.327) ( < 0.001), whereas improvement in daily living ability based on the UPDRSII assessment was -5.661 (95% CI: -7.632, -3.689) ( < 0.001).
The present findings demonstrate important clues on the therapeutic effect of cell therapy in alleviating motor impairment and daily living ability in PD patients.
在过去的四十年里，组织或细胞移植在帕金森病（PD）治疗中的应用日益广泛。帕金森病细胞治疗是一种很有前景的新疗法；然而，细胞移植治疗帕金森病的疗效尚完全不清楚。
对帕金森病患者细胞治疗的疗效进行荟萃分析和系统评价。
对10项研究进行系统的文献综述和荟萃分析，以评估细胞治疗对帕金森病患者的疗效。为此，我们将统一帕金森病评定量表（UPDRS）II和III量表评分与基线的变化进行比较，并评估移植相关不良事件的发生率。分别应用MINORS评分和I指数来评估研究质量和研究间的异质性。
文献检索得到10篇文章（n = 120）。基于UPDRSIII评估的运动功能改善为-14.044（95%CI：-20.761，-7.327）（P < 0.001），而基于UPDRSII评估的日常生活能力改善为-5.661（95%CI：-7.632，-3.689）（P < 0.001）。
目前的研究结果为细胞治疗缓解帕金森病患者运动障碍和日常生活能力的治疗效果提供了重要线索。
